Estrogen receptor modulators and uses thereof
AssigneeGenentech, Inc.
InventorsNicholas D. Smith, Mehmet Kahraman, Steven P. Govek, Johnny Y. Nagasawa, Andiliy G. Lai, Jackaline D. Julien, Mark R. Herbert, Karensa L. Douglas
Life of this patent
Estimating the term…
Abstract
Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
Claims18
A method of treating breast cancer comprising administering a therapeutically effective amount of (E)-3-(4-((E)-2-(2-Chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid, or a pharmaceutically acceptable salt thereof, to a patient.
The N-methylglucamine salt of (E)-3-(4-((E)-2-(2-Chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid.
A pharmaceutical composition comprising (E)-3-(4-((E)-2-(2-Chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid, or a pharmaceutically acceptable salt thereof, and an excipient or carrier.
A method of treating breast cancer, the method comprising administering a therapeutically effective amount of the N-methylglucamine salt of (E)-3-(4-((E)-2-(2-Chloro-4-fluorophenyl)-1-(1H-indazol5 -yl)but-1-en-1-yl)phenyl)acrylic acid to a patient.
Dependencies are inferred from the claim text.